SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of December
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrant’s name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address
of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits
the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private
issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82 -
|
EXHIBIT
NUMBER |
|
DESCRIPTION |
| |
|
|
| 99.1 |
|
News
Release Dated December 4, 2014 - Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® and Checkpoint Inhibitor Combination Preclinical
Data at AACR Tumor Immunology and Immunotherapy Conference |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Oncolytics Biotech Inc.
(Registrant) |
| |
|
|
| |
|
|
| Date:
December 4, 2014 |
By: |
/s/ Kirk Look |
| |
|
Kirk Look |
| |
|
Chief Financial Officer |
Exhibit 99.1
Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® and Checkpoint
Inhibitor Combination Preclinical Data at AACR Tumor Immunology and Immunotherapy Conference
CALGARY, Dec. 4, 2014 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics")
(TSX:ONC) (NASDAQ:ONCY) today announced a poster presentation by the Company's research collaborators, Vile et al., titled "Combination
Therapy with Reovirus and PD-1 Blockade Effectively Establishes Tumour Control Via Innate and Adaptive Immune Responses" was
made at the AACR Tumor Immunology and Immunotherapy Conference being held from December 1st through 4th in
Orlando, Florida.
"The preclinical data presented by our collaborators
demonstrates that REOLYSIN® increases the therapeutic activity of check point inhibitors," said Dr. Brad Thompson,
President and CEO of Oncolytics. "This finding is critical and supportive of the further investigation of REOLYSIN®
in combination with this important new class of therapeutics."
REOLYSIN® has been found to generate
both an anti-tumour response against reovirus-infected tumour cells and an immune reaction as those cells are killed. The collaborators'
research intended to exploit the immune components of reovirus therapy by testing REOLYSIN® in combination with
systemic checkpoint inhibition (using anti-PD-1 antibodies), which increases the immune system's ability to recognize and attack
cancer cells.
Testing of the combination was conducted in immune-competent
mouse models with established B16 melanomas. The investigators concluded that in this model, administering systemic anti-PD-1 antibody
with intra-tumoural reovirus significantly enhanced survival compared to intra-tumoural reovirus alone (p<0.01), with 40% of
the mice being cured long-term; that combination therapy of reovirus with PD-1 blockade delivers significant survival benefit by
augmenting tumour specific NK (natural killer) responses and specifically attenuating tumour specific immunosuppression; and, that
the combination of checkpoint inhibition therapy with reovirus oncolytic/immunotherapy represents a readily translatable method
to enhance the therapeutic value of either alone.
Two other abstracts examining the use of the reovirus,
titled "PDL-1 Blockade and Sunitinib Enhance the Efficiency of Oncolytic Viral Therapy" by Morris et al., and "Systemic
Oncolytic Reovirus for the Treatment of Primary and Secondary Brain Tumors" by Melcher et al., were submitted and presented
as posters. Copies of the abstracts and posters, when available, will be found on the Oncolytics website at: http://www.oncolyticsbiotech.com/for-investors/presentations.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®,
its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements, including the Company's expectations related to preclinical work with checkpoint
inhibitors, the translational study in brain cancer, future trials in these indications, and the Company's belief as to the potential
of REOLYSIN® as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's
actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others,
the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN® as
a cancer treatment, the tolerability of REOLYSIN® outside a controlled test, the success and timely completion of
clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN®, uncertainties related
to the research, development and manufacturing of pharmaceuticals, changes in technology, general changes to the economic environment
and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking
statements. Investors should consider statements that include the words "believes", "expects", "anticipates",
"intends", "estimates", "plans", "projects", "should", or other expressions that
are predictions of or indicate future events or trends, to be uncertain and forward-looking. Investors are cautioned against placing
undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except
as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
%CIK: 0001129928
For further information: TMX Equicom, Nick Hurst, 300 5th Ave. SW, 10th
Floor, Calgary, Alberta T2P 3C4, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@tmxequicom.com; TMX Equicom, Michael Moore, San Diego,
CA, Tel: 858.886.7813, mmoore@tmxequicom.com; Dian Griesel, Inc., Susan Forman, 335 West 38th Street, 3rd Floor, New York, NY 10018,
Tel: 212.825.3210, Fax: 212.825.3229, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 06:30e 04-DEC-14